Trial · NCT03572231
A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
NCT03572231, Completed, Astellas Pharma Singapore Pte. Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China. Trials, record NCT03572231. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03572231
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
- NCT number
- NCT03572231
- Status
- Completed
- Enrollment
- 805 participants, actual
- Lead sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Conditions
- Overactive Bladder (OAB)
- Interventions
- mirabegron, solifenacin, darifenacin, imidafenacin, tolterodine, oxybutynin, trospium, fesoterodine, propiverine
- First posted
- 2018-06-28
- Last updated
- 2020-04-22
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time from treatment initiation to discontinuation of Overactive Bladder (OAB) therapy | Up to 26 weeks | Discontinuation will include participants who discontinue mirabegron or antimuscarinics for more than 30 days (defined as the day after the last day of the prior supply to the next dispensing date). |
| Primary | Time from treatment initiation to switching to another OAB therapy or dose | Up to 26 weeks | Switching will be defined as a subset of initial mirabegron or antimuscarinics discontinuers who initiated another/different therapy(ies) within the follow-up period or within 30 days of being prescribed the first treatment. Change of treatment to another formulation of the same drug type under the same dosage will not be considered as switching. |
| Primary | Proportion of participants who discontinue OAB treatment | Up to 26 weeks | Discontinuation will include participants who discontinue mirabegron or antimuscarinics for more than 30 days (defined as the day after the last day of the prior supply to the next dispensing date). |
| Primary | Proportion of participants who switch to another treatment or dose | Up to 26 weeks | Switching will be defined as a subset of initial mirabegron or antimuscarinics discontinuers who initiated another/different therapy(ies) within the follow-up period or within 30 days of being prescribed the first treatment. Change of treatment to another formulation of the same drug type under the same dosage will not be considered as switching. |
| Secondary | Change from baseline in Overactive Bladder Questionnaire-Short Form (OAB-Q-SF) score | Baseline, weeks 10-14 and weeks 22-26 | Overactive Bladder Questionnaire-Short Form (OAB-Q-SF) is a participant-reported instrument consisting of 19 items that assess the degree to which a participant is bothered by OAB symptoms, and the degree of impact of OAB symptoms on daily life. Participants rate each item using a 6-point Likert Scale ranging from "Not at all" to "A very great deal" for the symptom bother items and "none of the time" to "All of the time" for the Health Related Quality of Life (HRQL) items. |
| Secondary | Change from baseline in Bladder Assessment Tool (BAT) score | Baseline, weeks 10-14 and weeks 22-26 | Bladder Assessment Tool (BAT) is a participant-reported instrument consisting of 17 questions regarding the symptoms, bothering, impacts and treatment satisfaction in the past 7 days. Scores range from 0 to 88, a reduction in BAT score indicates an improvement. |
| Secondary | Change from baseline in Overactive Bladder Symptom Scores (OABSS) score | Baseline, weeks 10-14 and weeks 22-26 | Overactive Bladder Symptom Scores (OABSS) is a participant-reported instrument consisting of 4 questions regarding daytime frequency, nocturia, urgency, and urgency incontinence; evaluates relevant symptoms from the participant's viewpoint. Scores range from 0 to 15 with a lower score indicating a mild presentation of overactive bladder syndrome and a higher score indicating moderate to severe presentation of overactive bladder syndrome. |
| Secondary | Change from baseline in Treatment Satisfaction-Visual Analog Scale (TS-VAS) score | Baseline, weeks 10-14 and weeks 22-26 | Treatment Satisfaction-Visual Analog Scale (TS-VAS) is a quantitative instrument assessing participant improvement in participants with OAB. A score of 10 on the TS-VAS indicates complete satisfaction, whereas a positive change from baseline indicates improvement. |
| Secondary | Identify factors associated with the effectiveness and persistence of a pharmacologic therapy for an OAB participant: Demographic Information | Baseline (up to Day 0) | Demographic information will be collected from participants for analysis. |
| Secondary | Identify factors associated with the effectiveness and persistence of a pharmacologic therapy for an OAB participant: OAB Medical History | Baseline (up to Day 0) | OAB medical history will be collected from participants for analysis. |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03572231
GET https://conductscience.org/api/trials/v1/NCT03572231/registered